[1]李 轶a,尚 立b.非酒精性脂肪肝病患者血清LncRNA PVT1 表达水平与胰岛素抵抗及肝纤维化的相关性研究[J].现代检验医学杂志,2023,38(05):80-85.[doi:10.3969/j.issn.1671-7414.2023.05.015]
　LI Yia,SHANG Lib.Correlation of Serum LncRNA PVT1 Expression Level with Insulin Resistance and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease[J].Journal of Modern Laboratory Medicine,2023,38(05):80-85.[doi:10.3969/j.issn.1671-7414.2023.05.015]
点击复制

非酒精性脂肪肝病患者血清LncRNA PVT1 表达水平与胰岛素抵抗及肝纤维化的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
80-85
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Correlation of Serum LncRNA PVT1 Expression Level with Insulin Resistance and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
文章编号:
1671-7414（2023）05-080-06
作者:
李 轶a; 尚 立b
（西安市第九医院a. 血管介入科；b. 消化内科，西安 710054）
Author(s):
LI Yia;  SHANG Lib
（a. Department of Vascular Intervention；b. Department of Gastroenterology， the Ninth Hospital of Xi’an City, Xi’an 710054, China）
关键词:
非酒精性脂肪肝病; 长链非编码RNA; 浆细胞瘤转化迁移基因1; 胰岛素抵抗; 肝纤维化
分类号:
R575；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.05.015
文献标志码:
A
摘要:
目的 探讨非酒精性脂肪肝病（nonalcoholic fatty liver disease，NAFLD）患者血清长链非编码RNA（long noncodingRNA，LncRNA）浆细胞瘤转化迁移基因1（plasmacytoma variant translocation gene 1，PVT1）表达水平与胰岛素抵抗和肝纤维化的相关性。方法 选择2020 年8 月～ 2022 年4 月西安市第九医院收治的143 例NAFLD 患者为观察对象（NAFLD 组），选择同期性别、年龄相匹配的健康志愿者（肝功能检测、肝脏超声检查结果均正常）140 例为对照组，收集入组人员资料及血清指标，采用RT-qPCR 检测血清LncRNA PVT1 表达，Pearson 分析NAFLD 患者血清LncRNAPVT1 与胰岛素抵抗、肝纤维化指标的相关性，Logistic 回归分析影响NAFLD 患者发生肝纤维化的因素。结果 NAFLD组血清AST（52.21±11.33 U/L），ALT（42.36±8.42 U/L），FBG[8.23（5.31~10.90）mmol/L]，HOMA-IR[2.31（1.52~3.95）]，TC（5.31±1.05 mmol/L），TG（1.89±0.93 mmol/L），LDL-C（3.51±0.92 mmol/L），PC Ⅲ（121.55±21.32 μg/L），C Ⅳ（78.56±15.42 μg/L），LN（110.36±25.41 μg/L）和HA 水平（93.15±16.85 μg/L）均高于对照组[24.35±8.53 U/L，28.62±6.35 U/L，5.34（9.65~6.71）mmol/L，1.68（1.26~2.61），4.26±0.53 mmol/L，1.23±0.35 mmol/L，2.82±0.75 mmol/L，95.34±12.63 μg/L，54.34±8.37 μg/L，84.21±16.55 μg/L 和82.43±14.26 μg/L]，而HDL-C（1.12±0.36 mmol/L）水平低于对照组（1.43±0.39 mmol/L），差异均有统计学意义（t/χ2=5.771 ～ 23.332，均P ＜ 0.001）；NAFLD 组患者血清LncRNA PVT1 表达水平为1.79±0.52，高于对照组的1.05±0.18，差异有统计学意义（t=15.929，P ＜ 0.001），HOMAIR＞ 2.69 的NAFLD 患者血清LncRNA PVT1 表达水平为2.18±0.45，显著高于HOMA-IR ≤ 2.69 患者血清LncRNAPVT1 表达水平（1.46±0.48）, 差异有统计学意义（t=9.188，P ＜ 0.001）；S0 ～ S4 期NAFLD 患者血清LncRNAPVT1 表达水平分别为1.41±0.35，1.72±0.40，2.01±0.33，2.31±0.32 和2.62±0.24，且随着肝纤维化分期增加，血清LncRNA PVT1 表达水平不断升高，差异有统计学意义（F=57.799，P ＜ 0.05）；相关性分析显示，NAFLD 患者血清LncRNA PVT1 与FBG，HOMA-IR，TC，TG，LDL-C，PC Ⅲ，C Ⅳ，LN 和HA 呈正相关性（r=0.498，0.488，0.550，0.422，0.435，0.451，0.404，0.525，0.421，均P ＜ 0.001），与HDL-C 呈负相关（r=-0.534，P ＜ 0.001）；Logistic 回归分析显示，HOMA-IR 和LncRNA PVT1 是NAFLD 患者发生肝纤维化的独立危险因素（P ＜ 0.05）。结论 NAFLD 患者血清LncRNA PVT1 表达水平升高，与胰岛素抵抗、肝纤维化相关，可能成为评估NAFLD 患者病情的指标。
Abstract:
Objective To investigate the correlation of serum long non-coding RNA (LncRNA) plasmacytoma variant translocation gene 1 (PVT1) expression level with insulin resistance and liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Methods From August 2020 to April 2022, 143 NAFLD patients admitted to the Ninth Hospital of Xi’an were taken as observation objects (NAFLD group), and 140 healthy volunteers (liver function test and liver ultrasonography results were normal) matched by gender and age were regarded as the control group. The data and serum indexes of the enrolled personnel were collected, and the expression of serum LncRNA PVT1 was detected by RT-qPCR. Pearson method was performed to analyze the correlation of serum LncRNA PVT1 with insulin resistance and liver fibrosis indicators in NAFLD patients, and Logistic regression was performed to analyze the factors affecting liver fibrosis in NAFLD patients. Results Serum AST (52.21±11.33 U/L), ALT (42.36±8.42 U/L), FBG[8.23 (5.31~10.90) mmol/L], HOMA-IR[2.31 (1.52~3.95)], TC (5.31±1.05 mmol/L), TG (1.89±0.93 mmol/L), LDL-C (3.51±0.92 mmol/L), PC Ⅲ (121.55±21.32 μg/L), C Ⅳ (78.56±15.42 μg/L), LN (110.36±25.41 μg/L) and HA (93.15±16.85 μg/L) in the NAFLD group were higher than that of the control group[24.35±8.53 U/L，28.62±6.35 U/L，5.34（9.65~6.71）mmol/L，1.68（1.26~2.61），4.26±0.53 mmol/L，1.23±0.35 mmol/L，2.82±0.75 mmol/L，95.34±12.63 μg/L，54.34±8.37 μg/L，84.21±16.55 μg/L，82.43±14.26 μg/L], and the level of HDL-C (1.12±0.36 mmol/L vs 1.43±0.39 mmol/L) were lower than that of the control group（1.43±0.39 mmol/L）, and the differences were statistically significant (t/χ2=5.771 ～ 23.332，all P<0.001). The expression level of LncRNA PVT1 in NAFLD group was 1.79±0.52, higher than that in control group (1.05±0.18), and the difference was statistically significant (t=15.929, P < 0.001). Serum LncRNA PVT1 expression level of NAFLD patients with HOMA-IR>2.69 was 2.18±0.45, significantly higher than that of patients with HOMA-IR ≤ 2.69 (1.46±0.48), and the difference was statistically significant (t=9.188, P<0.001).The expression levels of LncRNA PVT1 in patients with NAFLD in S0~S4 stage were 1.41±0.35, 1.72±0.40, 2.01±0.33, 2.31±0.32 and 2.62±0.24, respectively, with the increase of liver fibrosis stage, serum LncRNA PVT1 expression level was continuously increased, and the difference was statistically significant (F=57.799, P < 0.05). Correlation analysis showed that serum LncRNA PVT1 in NAFLD patients was positively correlated with FBG, HOMA-IR, TC, TG, LDL-C, PC III, CIV, LN and HA（r=0.498，0.488，0.550，0.422，0.435，0.451，0.404，0.525，0.421，all P<0.001), and negatively correlated with HDL-C (r=-0.534, P<0.001).Logistic regression analysis showed that HOMA-IR and LncRNA PVT1 were independent risk factors for liver fibrosis in NAFLD patients (P ＜ 0.05). Conclusion The expression level of serum LncRNA PVT1 in NAFLD patients was increased, which was related to insulin resistance and liver fibrosis, and may be an indicator for evaluating the condition of NAFLD patients.

参考文献/References:

[1] MAKRI E, GOULAS A, POLYZOS S A. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease[J]. Archives of Medical Research, 2021, 52(1): 25-37.
[2] YOUNOSSI Z M, LOOMBA R, ANSTEE Q M, et al. Diagnostic modalities for nonalcoholic fatty liver disease,nonalcoholic steatohepatitis,and associated fibrosis[J]. Hepatology, 2018, 68(1): 349-360.
[3] LI Yazhou, LIU Peixiao, WEI Feipeng. Long non-coding RNA MBI-52 inhibits the development of liver fibrosis by regulating the microRNA-466g/SMAD4 signaling pathway[J]. Molecular Medicine Reports, 2022, 25(1): 33.
[4] 崔士猛, 杜渐, 罗海峰, 等. 长链非编码RNA PVT1通过miR-17-5p 调控肝癌细胞增殖与迁移的机制研究[J]. 安徽医科大学学报, 2020, 55(6): 932-936. CUI Shimeng, DU Jian, LUO Haifeng, et al. Long non-coding RNA PVT1 regulates cell proliferation and metastasis through miR-17-5p in hepatocellular carcinoma[J]. Acta Universitatis Medicinalis Anhui, 2020, 55(6): 932-936.
[5] ZHANG Lin, ZHANG Dan, QIN Zhenying, et al. The role and possible mechanism of long noncoding RNA PVT1 in modulating 3T3-L1 preadipocyte proliferation and differentiation[J]. IUBMB Life, 2020, 72(7): 1460-1467.
[6] ZHENG Jianjian, YU Fujun, DONG Peihong, et al. Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152[J].Oncotarget, 2016, 7(39): 62886-62897.
[7] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018 [J]. Chinese Journal of Cardiology, 2018, 46(10): 760-789.
[8] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015 年更新版)[J]．临床肝胆病杂志, 2015, 31(12): 1941-1960. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseaes, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update [J]. Journal of Clinical Hepatology, 2015, 31(12): 1941-1960.
[9] 朱琳, 林延润, 杨发达, 等．PCOS 患者胰岛素释放试验峰值后移与胰岛素分泌总量及敏感性的特征分析[J]．现代检验医学杂志, 2022, 37(5): 154-158. ZHU Lin, LIN Yanrun, YANG Fada, et al. Analysis of the relationship between the peak shift of insulin release test and total insulin secretion and sensitivity in patients with PCOS[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 154-158.
[10] 刘小纪, 何淳, 解宏杰．血清YKL-40 对非酒精性脂肪肝肝纤维化的预测作用[J]．标记免疫分析与临床,2020, 27(1): 128-131, 167. LIU Xiaoji, HE Chun, XIE Hongjie. The predictive effect of serum YKL-40 on liver fibrosis in nonalcoholic fatty liver disease[J]. Labeled Immunoassays and Clinical Medicine, 2020, 27(1): 128-131, 167.
[11] QIN Rong, HUANG Weikang, HUANG Yun, et al. LncRNA MEG3 modulates hepatic stellate cell activation by sponging miR-145 to regulate PPARγ[J].Molecular Medicine Reports, 2022, 25(1): 3.
[12] 张丽云, 邓家琦, 张双, 等. 长链非编码RNA EXOC7 在非酒精性脂肪性肝病中的表达及临床意义[J]. 临床肝胆病杂志, 2020, 36(2): 391-394. ZHANG Liyun, DENG Jiaqi, ZHANG Shuang, et al. Expression and significance of the long non-coding RNA EXOC7 in nonalcoholic fatty liver disease[J].Journal of Clinical Hepatology, 2020, 36(2): 391- 394.
[13] HE Guannan, BAO Naren, WANG Shuang, et al. Ketamine induces ferroptosis of liver cancer cells by targeting LncRNA PVT1/miR-214-3p/GPX4[J]. Drug Design, Development and Therapy, 2021, 15: 3965-3978.
[14] 叶凤, 肖锋, 宋彩霞. 长链非编码RNA PVT1 通过调控miR-455 的表达影响糖尿病肾病足细胞损伤和凋亡[J]. 中国中西医结合肾病杂志, 2020, 21(7):608-610. YE Feng, XIAO Feng, SONG Caixia. Long chain non coding RNA PVT1 affects podocyte injury and apoptosis in diabetes nephropathy by regulating the expression of miR-455[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2020, 21(7): 608-610.
[15] ZHANG Han, NIU Qinghui, LIANG Kun, et al. Effect of LncPVT1/miR-20a-5p on lipid metabolism and insulin resistance in NAFLD[J]. Diabetes Metabolic Syndrome and Obesity, 2021, 14(1): 4599-4608.
[16] CHENG Yinqin, HU Qiaosheng, ZHOU Jie. Silencing of LncRNA PVT1 ameliorates streptozotocin-induced pancreatic β cell injury and enhances insulin secretory capacity by regulating miR-181a-5p[J]. Canadian Journal of Physiology and Pharmacology, 2021, 99(3): 303-312.
[17] FENG Kun, LIU Yu, XU Lijuan, et al. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor [J].Biomed Pharmacother, 2018, 104: 686-698.
[18] ZHANG Rui, LI Jinbo, HUANG Tao, et al. Danggui buxue tang suppresses high glucose-induced proliferation and extracellular matrix accumulation of mesangial cells via inhibiting LncRNA PVT1[J].American Journal of Translational Research, 2017, 9(8): 3732-3740.
[19] 王艳, 邓卫平, 李瑞明. 血清外泌体LncRNA NEAT1在非酒精性脂肪性肝病肝纤维化中的诊断价值[J].中西医结合肝病杂志, 2021, 31(10): 933-938. WANG Yan, DENG Weiping, LI Ruiming. Diagnostic value of serum exosomal LncRNA NEAT 1 for liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2021, 31(10): 933-938.
[20] YU Fujun, DONG Buyuan, DONG Peihong, et al. Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway[J]. Molecular and Cellular Biochemistry, 2020, 465(1): 115-123.

相似文献/References:

[1]张 振,李 芬.ceRNA与肿瘤[J].现代检验医学杂志,2016,31(04):128.[doi:10.3969/j.issn.1671-7414.2016.04.036]
[2]白盈盈,朱光旭,潘兴华.长链非编码RNA对结直肠癌潜在诊断价值的研究进展[J].现代检验医学杂志,2018,33(01):161.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[3]洪　宏,袁建芬,喻海忠.乳腺癌患者血清长链非编码RNA ATB 表达水平检测及临床诊断价值[J].现代检验医学杂志,2020,35(02):22.[doi:10.3969 ／ j.issn.1671-7414.2020.02.007]
　HONG Hong,YUAN Jian-fen,YU Hai-zhong.Detection and Clinical Diagnosis Value of Serum Long Non-codingRNA ATB in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):22.[doi:10.3969 ／ j.issn.1671-7414.2020.02.007]
[4]李　悦,徐焕铭,樊　华.基于TCGA 数据对60 岁以上不同分层急性髓系白血病患者相关lncRNA 的基因信息学分析[J].现代检验医学杂志,2020,35(03):20.[doi:10.3969/j.issn.1671-7414.2020.03.005]
　LI Yue,XU Huan-ming,FAN Hua.Genetic Informatics Analysis of lncRNA Related to Patients with Different Stratified Acute Myeloid Leukemia Over 60 Years Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(05):20.[doi:10.3969/j.issn.1671-7414.2020.03.005]
[5]梁晓虎,郭俊霞,雷尚昆.食管癌组织中lnc RNA DNAJC3-AS1的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
　LIANG Xiao-hu,GUO Jun-xia,LEI Shangkun.Expression of Lnc RNA DNAJC3-AS1 in Esophageal Carcinoma Tissues and Its Correlation with Clinicopathological Features[J].Journal of Modern Laboratory Medicine,2021,36(05):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
[6]刘　霄a,黄晓燕b,王建华a.长链非编码RNASNHG9在不同肿瘤中的最新研究进展[J].现代检验医学杂志,2021,36(04):176.[doi:10.3969/j.issn.1671-7414.2021.04.038]
　LIU Xiaoa,HUANG Xiao-yanb,WANG Jian-huaa.Reasearch Progress of Long Non-coding RNA SNHG9 in Different Tumors[J].Journal of Modern Laboratory Medicine,2021,36(05):176.[doi:10.3969/j.issn.1671-7414.2021.04.038]
[7]朱　娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
　ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[8]刘立民,刘雪香,邹　燕,等.长链非编码RNA调控CD4+T淋巴细胞增殖分化和在免疫性疾病中的最新研究进展[J].现代检验医学杂志,2021,36(06):200.[doi:10.3969/j.issn.1671-7414.2021.06.044]
　LIU Li-min,LIU Xue-xiang,ZOU Yan,et al.Roles of lncRNA in Regulating the Proliferation, Differentiation of CD4+T Lymphocytes and Immune Diseases[J].Journal of Modern Laboratory Medicine,2021,36(05):200.[doi:10.3969/j.issn.1671-7414.2021.06.044]
[9]张文娟,郭 逸,段 勇,等.健康献血者机采血小板储存中LncRNA LIPCAR 的表达及初步研究[J].现代检验医学杂志,2023,38(03):119.[doi:10.3969/j.issn.1671-7414.2023.03.021]
　ZHANG Wen-juan,GUO Yi,DUAN Yong,et al.Expression and Preliminary Study of LncRNA LIPCAR in Platelet Storage of Mechanically Collected Platelets from Healthy Blood Donors[J].Journal of Modern Laboratory Medicine,2023,38(05):119.[doi:10.3969/j.issn.1671-7414.2023.03.021]
[10]商 静a,刘 波a,李小侠b,等.陕西职业学校视力残疾学生患非酒精性脂肪肝病及临床实验室相关指标调查[J].现代检验医学杂志,2023,38(03):199.[doi:10.3969/j.issn.1671-7414.2023.03.037]
　SHANG Jinga,LIU Boa,LI Xiao-xiab,et al.An Investigation of Non-alcoholic Fatty Liver and Clinical Laboratoryrelated Indicators in Shaanxi Province’s Vocational Students with Visual Disabilities[J].Journal of Modern Laboratory Medicine,2023,38(05):199.[doi:10.3969/j.issn.1671-7414.2023.03.037]

备注/Memo

备注/Memo:
基金项目：西安市第九医院科研项目（编号：2020-7）：经皮瘤内注射平阳酶素碘油化疗乳剂治疗骶骨背索瘤。
作者简介：李轶（1990-），男，硕士研究生，主治医师，研究方向：医学影像和介入治疗，E-mail：liyi888ly@126.com。
通讯作者：尚立（1980-），女，硕士研究生，副主任医师，研究方向：消化道早癌，E-mail：bwwyukvhcui35@163.com。
更新日期/Last Update: 2023-09-15